Study to Evaluate Tumour Response in Cancer Patients With Advanced Hepatocellular Carcinoma (Liver Cancer) With AMT2003
A Prospective, Open, Single-arm, Multicenter Phase II Clinical Trial to Evaluate the Tumour Response and Safety in Patients With Advanced Primary Hepatocellular Carcinoma Treated With AMT2003
Sponsor: Auron Healthcare GmbH
Terminated
Lack of efficacy
Other terminated trials from Auron Healthcare GmbH
- Gastrointestinal Cancer · Phase PHASE2/PHASE3 · Mar 2010
- Colorectal Carcinoma · Phase PHASE2/PHASE3 · Jan 2010
More terminations from Auron Healthcare GmbH
This PHASE2 trial investigates Hepatocellular Carcinoma and is currently terminated or withdrawn. Auron Healthcare GmbH leads this study, which shows 5 recorded versions since 2007 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2
First recorded
Mar 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Auron Healthcare GmbH
For direct contact, visit the study record on ClinicalTrials.gov .